ZURAHealthcare · BiotechnologyThe 7 Wall Street analysts covering Zura Bio Ltd. hold a median 12-month price target of $20 — +392.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Zura Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (67): The shares have been drifting up relative to others.
Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ZURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +392.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Guggenheim | Maintains | Buy | $15 → $20 |
| 12 Aug 2026 | Wedbush | Maintains | Outperform | $15 → $22 |
| 8 July 2026 | William Blair | Initiates | Outperform | — |
| 8 July 2026 | William Blair | Initiates | Outperform | — |
| 1 July 2026 | Wedbush | Reiterates | Outperform | — |
| 1 July 2026 | Wedbush | Reiterates | Outperform | $15 |
| 23 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 9 Feb 2026 | Wedbush | Initiates | Outperform | — |
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Nov 2025 | Clear Street | Initiates | Buy | — |
| 30 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 9 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 26 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 26 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 26 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZURA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Zura Bio Ltd. returned +8.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 62% of US stocks
Cheaper than 40% of US stocks
Cheaper than 74% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zura Bio Ltd. has a market value of $389.2M and an enterprise value of $201.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$85.7M.
Free cash flow in the twelve months to 30 June 2026: −$77.6M.
Trailing P/E: 7.9×; forward P/E: −6.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Zura Bio Ltd. employs 40 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zura Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zura Bio reported that on October 26, 2026, it granted options to purchase up to 250,200 Class A ordinary shares to five newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The grants represent equity-based compensation associated with five new hires and are relevant to tracking Zura Bio’s share-based awards.
Zura Bio announced financial results for the third quarter ended September 30, 2026, and provided recent corporate updates. The excerpt notes continued execution on its tibulizumab development plan.
Why it matters — The update gives ZURA watchers information about the company's quarterly results and progress on its stated development plan.
Zura Bio announced that members of its management team will participate in the Cantor Global Healthcare Conference in New York, NY, including a fireside chat scheduled for Wednesday, September 9, 2026. The company is a clinical-stage biotechnology firm developing medicines for autoimmune and inflammatory diseases.
Why it matters — A ZURA watcher would care because the management team's participation at a major investor conference offers an opportunity for additional company exposure and investor engagement.
Zura Bio reported that on August 20, 2026, it granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees. The grants were made under Nasdaq Listing Rule 5635(c)(4).
Why it matters — This item signals Zura's ongoing hiring and equity-based incentive activity, which ZURA watchers may track as part of the company's workforce and compensation developments.
Zura Bio Limited reported its financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. Management highlighted strong execution across the company's tibulizumab programs, noting that enrollment is now complete.
Why it matters — ZURA watchers would care because the report confirms progress on the company's lead tibulizumab programs and provides a snapshot of its financial standing for the quarter.
The 7 Wall Street analysts covering Zura Bio Ltd. have a median 12-month price target of $20, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Zura Bio Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zura Bio Ltd. 31 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Zura Bio Ltd. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (67 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +392.6% from the last close, and Ticker Nerd's factor model ranks Zura Bio Ltd. 31 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zura Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.
Zura Bio Ltd. returned +8.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. The company is building a multi-asset immunology pipeline centered on dual-pathway antibodies designed to address immune system imbalance and improve treatment options for patients with serious, underserved conditions.
The most recent item we track (Business Wire, 27 Oct 2026): "Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Zura Bio reported that on October 26, 2026, it granted options to purchase up to 250,200 Class A ordinary shares to five newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. The company is building a multi-asset immunology pipeline centered on dual-pathway antibodies designed to address immune system imbalance and improve treatment options for patients with serious, underserved conditions. Its current programs include tibulizumab, torudokimab, and crebankitug, each targeting distinct immune pathways involved in inflammation and autoimmune activity. Zura Bio Limited concentrates on therapeutic areas such as hidradenitis suppurativa, systemic sclerosis, alopecia areata, and other immune-mediated disorders. By advancing differentiated antibody-based therapies, the company plays a specialized role in the biotechnology market as a developer of precision treatments for complex inflammatory diseases. Zura Bio Limited is headquartered in Henderson, Nevada.
CEO Dr. Sandeep Chidambar Kulkarni M.D. · 40 employees · United States · https://zurabio.com
